Evia Bio, founded in Minneapolis, Minnesota, is a life sciences innovation company dedicated to advancing cryopreservation technologies. Its core mission is to develop non-DMSO cryopreservation solutions for the cell therapy industry, aiming to enhance the viability and performance of preserved cells. The company offers a range of products and services including CryoConnect, CryoChats™, CryoX™, CryoU, and CryoToons™, which focus on assessing and improving current cryopreservation protocols through AI-driven, non-toxic cryoprotectant platforms.
Evia Bio has attracted notable investors and experts in the life sciences field, contributing to its rapid growth and innovation. The company has achieved significant milestones in developing non-DMSO cryoprotectants that are safer and more effective than traditional methods. Its impact on the cell therapy industry is profound, providing critical advancements that improve the quality and longevity of preserved cells, thereby enhancing therapeutic outcomes.
